Sema4 Holdings Corp. SMFR
We take great care to ensure that the data presented and summarized in this overview for Sema4 Holdings Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SMFR
Top Purchases
Top Sells
About SMFR
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Insider Transactions at SMFR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Kevin Feeley CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,728
-11.68%
|
$283,328
$76.75 P/Share
|
|
Dec 16
2024
|
Kevin Feeley CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,197
+18.39%
|
-
|
|
Dec 16
2024
|
Katherine Stueland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,501
-12.86%
|
$798,076
$76.75 P/Share
|
|
Dec 16
2024
|
Katherine Stueland Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+18.68%
|
-
|
|
Dec 09
2024
|
Katherine Stueland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,661
-5.5%
|
$278,236
$76.37 P/Share
|
|
Dec 09
2024
|
Katherine Stueland Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,547
+8.96%
|
-
|
|
Dec 09
2024
|
Kevin Feeley CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,137
-4.4%
|
$86,412
$76.37 P/Share
|
|
Dec 09
2024
|
Kevin Feeley CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,462
+8.69%
|
-
|
|
Dec 02
2024
|
Kevin Feeley CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
263
-1.11%
|
$20,514
$78.39 P/Share
|
|
Dec 01
2024
|
Kevin Feeley CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
718
+2.94%
|
-
|
|
Nov 22
2024
|
Kevin Feeley CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
9,981
-11.28%
|
$758,556
$76.38 P/Share
|
|
Nov 21
2024
|
Kevin Feeley CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,019
-4.92%
|
$865,368
$72.34 P/Share
|
|
Nov 20
2024
|
Jason Ryan |
SELL
Open market or private sale
|
Indirect |
15,490
-63.58%
|
$1,068,810
$69.57 P/Share
|
|
Nov 19
2024
|
Jason Ryan |
SELL
Open market or private sale
|
Indirect |
31,510
-25.93%
|
$2,237,210
$71.49 P/Share
|
|
Nov 19
2024
|
Jason Ryan |
SELL
Bona fide gift
|
Indirect |
141,356
-75.05%
|
-
|
|
Nov 18
2024
|
School Of Medicine At Mount Sinai Icahn |
SELL
Open market or private sale
|
Direct |
126,782
-4.45%
|
$8,874,740
$70.78 P/Share
|
|
Nov 18
2024
|
Katherine Stueland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
22,307
-5.05%
|
$1,539,183
$69.4 P/Share
|
|
Nov 15
2024
|
School Of Medicine At Mount Sinai Icahn |
SELL
Open market or private sale
|
Direct |
20,359
-0.71%
|
$1,404,771
$69.78 P/Share
|
|
Nov 15
2024
|
Katherine Stueland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,108
-3.44%
|
$1,640,668
$71.65 P/Share
|
|
Oct 31
2024
|
School Of Medicine At Mount Sinai Icahn |
SELL
Open market or private sale
|
Direct |
865,800
-23.2%
|
$64,935,000
$75.0 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 277K shares |
|---|---|
| Other acquisition or disposition | 414K shares |
| Open market or private purchase | 431K shares |
| Open market or private sale | 2.12M shares |
|---|---|
| Bona fide gift | 215K shares |